Symbols

CVM

CEL-SCI·AMEX

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CVM

Cel-Sci Corporation

A company that develops immunotherapeutic agents and peptides to treat cancer and bacterial and viral infections

Industry

Biological Technology

Established Date

03/22/1983

Listing Date

06/05/1997

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

09-30

Website

www.cel-sci.com

Security Type

Common stock

Office address

8229 Boone Blvd. Suite 802 Vienna Virginia 22182

Business

Introduction

CEL-SCI Corporation was incorporated in Colorado on March 22, 1983 to fund research and development in the biomedical sciences, and ultimately to market and sell products. CEL-SCI Corporation is committed to research and development aimed at improving the treatment of cancer and other diseases by harnessing the immune system — the body's natural defense system. The company is currently working on Multikine, an investigational phase 3 immunotherapy for certain head and neck cancers, and L.E.A.P.S. (Ligand Epitope Antigen Reporting System) technology, including several product candidates for potential treatments for rheumatoid arthritis.

Company Financials

EPS

CVM has released its 2025 Q3 earnings. EPS was reported at -1.36, versus the expected 0, missing expectations. The chart below visualizes how CVM has performed over recent quarters, highlighting trends in earnings surprises.